Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

BACKGROUND: Adalimumab is a fully human, monoclonal antibody against tumor necrosis factor that is approved in Western countries for the treatment of moderately to severely active ulcerative colitis (UC). METHODS: This 52-week, phase 2/3, randomized, double-blind study evaluated adalimumab for induc...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Yasuo, Motoya, Satoshi, Hanai, Hiroyuki, Matsumoto, Takayuki, Hibi, Toshifumi, Robinson, Anne M., Mostafa, Nael M., Chao, Jingdong, Arora, Vipin, Camez, Anne, Thakkar, Roopal B., Watanabe, Mamoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2013
Materias:
Original Article—Alimentary Tract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3925299/
https://www.ncbi.nlm.nih.gov/pubmed/24363029
http://dx.doi.org/10.1007/s00535-013-0922-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3925299/
https://www.ncbi.nlm.nih.gov/pubmed/24363029
http://dx.doi.org/10.1007/s00535-013-0922-y

Ejemplares similares